International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
-
- Daniel A. Arber
- 1University of Chicago, Chicago, IL;
-
- Attilio Orazi
- 2Texas Tech University Health Sciences Center El Paso, El Paso, TX;
-
- Robert P. Hasserjian
- 3Massuchusetts General Hospital, Boston, MA;
-
- Michael J. Borowitz
- 4Johns Hopkins University, Baltimore, MD;
-
- Katherine R. Calvo
- 5National Institutes of Health Clinical Center, Bethesda, MD;
-
- Hans-Michael Kvasnicka
- 6Helios Universitätsklinikum Wuppertal, Wuppertal, Germany;
-
- Sa A. Wang
- 7University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Adam Bagg
- 8University of Pennsylvania, Philadelphia, PA;
-
- Tiziano Barbui
- 9Clinical Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy;
-
- Susan Branford
- 10Centre for Cancer Biology, Adelaide, SA, Australia;
-
- Carlos E. Bueso-Ramos
- 7University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Jorge E. Cortes
- 11Georgia Cancer Center, Augusta, GA;
-
- Paola Dal Cin
- 12Brigham and Women’s Hospital, Boston, MA;
-
- Courtney D. DiNardo
- 7University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Hervé Dombret
- 13Université Paris Cité, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France;
-
- Eric J. Duncavage
- 14Washington University in St Louis, St. Louis, MO;
-
- Benjamin L. Ebert
- 15Dana-Farber Cancer Institute, Boston, MA;
-
- Elihu H. Estey
- 16University of Washington, Seattle, WA;
-
- Fabio Facchetti
- 17University of Brescia School of Medicine, Brescia, Italy;
-
- Kathryn Foucar
- 18University of New Mexico, Albuquerque, NM;
-
- Naseema Gangat
- 19Mayo Clinic, Rochester, MN;
-
- Umberto Gianelli
- 20Università degli Studi di Milano, Milan, Italy;
-
- Lucy A. Godley
- 1University of Chicago, Chicago, IL;
-
- Nicola Gökbuget
- 21Goethe University, Frankfurt, Germany;
-
- Jason Gotlib
- 22Stanford University School of Medicine, Stanford, CA;
-
- Eva Hellström-Lindberg
- 23Karolinska Institutet, Solna, Sweden;
-
- Gabriela S. Hobbs
- 3Massuchusetts General Hospital, Boston, MA;
-
- Ronald Hoffman
- 24Mount Sinai Medical Center, New York, NY;
-
- Elias J. Jabbour
- 7University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Jean-Jacques Kiladjian
- 13Université Paris Cité, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France;
-
- Richard A. Larson
- 1University of Chicago, Chicago, IL;
-
- Michelle M. Le Beau
- 1University of Chicago, Chicago, IL;
-
- Mignon L.-C. Loh
- 25Seattle Children’s Hospital, Seattle, WA;
-
- Bob Löwenberg
- 26Erasmus Medical Center, Rotterdam, Netherlands;
-
- Elizabeth Macintyre
- 27Université Paris Cité, Paris, France;
-
- Luca Malcovati
- 28University of Pavia, Pavia, Italy;
-
- Charles G. Mullighan
- 29St. Jude Children’s Research Hospital, Memphis, TN
-
- Charlotte Niemeyer
- 30University of Freiburg Medical Center, Freiburg um Breisgau, Germany;
-
- Olatoyosi M. Odenike
- 1University of Chicago, Chicago, IL;
-
- Seishi Ogawa
- 31Kyoto University, Kyoto, Japan;
-
- Alberto Orfao
- 32University of Salamanca, Salamanca, Spain;
-
- Elli Papaemmanuil
- 33Memorial Sloan-Kettering Cancer Center, New York, NY;
-
- Francesco Passamonti
- 28University of Pavia, Pavia, Italy;
-
- Kimmo Porkka
- 34Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland;
-
- Ching-Hon Pui
- 29St. Jude Children’s Research Hospital, Memphis, TN
-
- Jerald P. Radich
- 35Fred Hutchinson Cancer Research Center, Seattle, WA;
-
- Andreas Reiter
- 36University Hospital Mannheim, Mannheim, Germany;
-
- Maria Rozman
- 37University of Barcelona, Barcelona, Spain;
-
- Martina Rudelius
- 38Ludwig Maximilians University Munich, Munich, Germany;
-
- Michael R. Savona
- 39Vanderbilt University School of Medicine, Nashville, TN;
-
- Charles A. Schiffer
- 40Karmanos Cancer Institute, Detroit, MI;
-
- Annette Schmitt-Graeff
- 41Albert-Ludwigs-University Freiburg, Freiburg im Breisgau, Germany
-
- Akiko Shimamura
- 15Dana-Farber Cancer Institute, Boston, MA;
-
- Jorge Sierra
- 43Hospital Santa Creu i Sant Pau, Barcelona, Spain;
-
- Wendy A. Stock
- 1University of Chicago, Chicago, IL;
-
- Richard M. Stone
- 15Dana-Farber Cancer Institute, Boston, MA;
-
- Martin S. Tallman
- 44Lurie Children’s Hospital, Chicago, IL;
-
- Jürgen Thiele
- 45University of Cologne, Köln, Germany;
-
- Hwei-Fang Tien
- 46National Taiwan University Hospital, Taipei City, Taiwan;
-
- Alexandar Tzankov
- 47Medical University Basel, Basel, Switzerland;
-
- Alessandro M. Vannucchi
- 48University of Florence and AOU Careggi, Florence, Italy;
-
- Paresh Vyas
- 49University of Oxford, Oxford, United Kingdom;
-
- Andrew H. Wei
- 50Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;
-
- Olga K. Weinberg
- 51University of Texas Southwestern, Dallas, TX;
-
- Agnieszka Wierzbowska
- 52Medical University of Lodz, Lodz, Poland; and
-
- Mario Cazzola
- 28University of Pavia, Pavia, Italy;
-
- Hartmut Döhner
- 53University Hospital Ulm, Ulm, Germany
-
- Ayalew Tefferi
- 19Mayo Clinic, Rochester, MN;
抄録
<jats:title>Abstract</jats:title><jats:p>The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.</jats:p>
収録刊行物
-
- Blood
-
Blood 140 (11), 1200-1228, 2022-09-15
American Society of Hematology